Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Caris Life Sciences Inc maintains a gross margin of 75.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.19%, while the net margin is 27.98%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CAI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CAI competes directly with industry leaders such as IMVT and CRSP. With a market capitalization of $5.69B, it holds a significant position in the sector. When comparing efficiency, CAI's gross margin of 75.43% stands against IMVT's N/A and CRSP's 100.00%. Such benchmarking helps identify whether Caris Life Sciences Inc is trading at a premium or discount relative to its financial performance.
